BMRN vs NEPH · P/E 40, rev $2.85B vs P/E 48, rev $14.2M
Biomarin Pharmaceutical Inc (BMRN) versus Nephros Inc (NEPH) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Nephros Inc (NEPH) is a medical instruments & supplies company listed on US.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported NEPH revenue for 2024-12-31 was $14.2M. Net income was $74.0K. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. NEPH currently screens at market cap $40.9M and trailing P/E 48.3.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. NEPH currently screens at market cap $40.9M and trailing P/E 48.3.
Not investment advice. Open the BMRN and NEPH stock pages for the full models.
Not investment advice.